If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
253
results.
Updated on
07/05/2026 [07:05:00]
Results 75 to 100 of 253
Absstract of: WO2024214013A1
A nanoparticle is described, which comprises a plurality of therapeutic molecules arranged in the form of a spherical micelle, suitable for the localized delivery and release of mycophenolic acid, and therefore effective in the treatment of autoimmune diseases, fibrotic diseases and/or organ rejection diseases, in particular of the lungs. A pharmaceutical composition comprising the nanoparticle in a pharmaceutically acceptable vehicle, and a method for manufacturing said nanoparticle are also described.
Absstract of: WO2024211857A1
This disclosure features novel lipid nanoparticle formulations and uses thereof. The lipid nanoparticle ("LNP") includes an encapsulated therapeutic agent and an aqueous solution comprising a salt and an anionic polymer, wherein the salt and the anionic polymer are dissolved in the aqueous solution, thereby forming polymer coated lipid nanoparticle ("PCLNP"). Lipid nanoparticles of this disclosure are useful in the process of lyophilization or freeze drying and decrease nanoparticle aggregation and maintain efficacy once reconstituted.
Absstract of: WO2024211865A2
The current disclosure relates to lipid-based compositions and methods of administering therapeutic agents relating thereto. In particular, the disclosure relates to lipid-like substituted aryl and/or heteroaryl compounds, substituted piperazines, and/or other aryl and/or heteroaryl lipid compounds as LNP delivery materials that may be incorporated into lipid-based compositions to increase efficiency of delivery of a therapeutic agent(s) to tissues of a subject.
Absstract of: CN121943849A
本发明公开了一种基于同源细胞膜包裹喹唑啉酮衍生物的载药纳米颗粒及其制备方法和应用，采用PLGA包裹药物分子的纳米粒子为核，并在其表面包裹食管鳞癌细胞膜壳层形成核壳结构的载药纳米颗粒，载药纳米颗粒具有生物相容性和食管鳞癌靶向性，载药纳米颗粒携带肿瘤特异性抗原、受体和表面粘附分子，能够将喹唑啉酮衍生物靶向递送到食管鳞癌部位，而对其它组织器官不会造成毒副作用，有效发挥抗食管鳞癌的作用，载药纳米颗粒与食管鳞癌细胞膜表面成分接近，能够降低被免疫系统视为异物的可能性，进而提高药物分子的利用率，载药纳米颗粒具有缓释作用，能够实现药物分子的持续缓慢释放，达到长时间维持一定血药浓度以杀伤癌细胞的效果。
Absstract of: CN121943846A
本发明公开了一种面向肿瘤诊断的磁/pH双响应微纳机器人，涉及磁/pH双响应与量子传感的微纳机器人MNR(Fe3O4@PDA‑FNDs@CaP)的制备及其检测应用方法。该技术针对现有微纳机器人靶向效率低、治疗过程缺乏动态反馈的问题，提供了一种“主动靶向治疗‑量子即时检测”的诊疗一体化策略。该微纳机器人以磁性Fe3O4为核心，依次构建不完全包覆PDA中间层、FNDs量子传感层、葡萄糖氧化酶触发层以及pH响应CaP外壳。不完全包覆的PDA层是诱导铁死亡治疗的关键结构，CaP外壳在靶向环境中分解，实现功能组分的受控释放并触发级联反应，从而增强铁死亡治疗效率。同时利用FNDs弛豫时间的变化，实现对铁死亡过程中·OH产生浓度的检测，实现对治疗效果的即时监测。
Absstract of: CN121943847A
本申请提供了一种海参肽微球复合物，其为壳聚糖类似物包裹海参肽的纳米粒；所述壳聚糖类似物为壳聚糖、羧甲基壳聚糖、羟丙基壳聚糖中的任一种。本申请提供的HP‑CS‑NPS（或HPStide®‑N）为开发高效、稳定、多功能的妇科护理、化妆品及护肤品提供了创新的活性成分解决方案，尤其适用于敏感性皮肤、痘痘肌的护理与修护。
Absstract of: CN121943854A
本发明涉及一种共递送铂类衍生物和小核酸的脂质纳米粒及其制备方法和应用，属于生物医药技术领域；所述脂质纳米粒包含脂质双分子层和其包载的小核酸，所述脂质双分子层包括阳离子聚合物、聚乙二醇化铂类衍生物、聚乙二醇化磷脂、结构脂质和结构磷脂；所述小核酸为siRNA、ASO或shRNA，所述小核酸与所述脂质双分子层的亲水性头部基团结合。本发明制备的脂质纳米粒将两种药物封装于同一体系，能够实现二者的同步递送；脂质纳米粒能保护小核酸在循环中不被降解，主动靶向肿瘤组织，增加药物在肿瘤部位的蓄积；脂质纳米粒能利用肿瘤微环境特性促进核酸药物溶酶体释放，具有良好的应用前景。
Absstract of: WO2026090531A1
A process for forming composite nanoparticles includes (a) mixing a first liquid with water, the first liquid comprising nanocrystal, hydrophobic organic molecule, or a combination thereof, and an organic solvent, forming particle core comprising the nanocrystal, hydrophobic organic molecule, or a combination thereof suspended in the water; and (b) mixing the particle core suspended in water with a second liquid, the second liquid comprising a stabilizer and the organic solvent, stabilizing the particle core comprising the nanocrystal, hydrophobic organic molecule, or a combination thereof with the stabilizer, and forming the composite nanoparticles. A time delay between steps (a) and (b) is about 2 millisecond (ms) to about 1 second.
Absstract of: WO2026090328A1
The present disclosure relates to a lipid nanoparticle (LNP) composition for the delivery of a polynucleotide encoding WNT7a and methods of treating skeletal muscle fibro-adipogenic progenitor (FAP) adipogenesis.
Absstract of: WO2026090491A1
The present disclosure is directed to nanobody-siRNA conjugates and methods of producing and using same. The nanobody-siRNA conjugates include a nanobody that may direct the conjugate to a target cell. The nanobody-siRNA conjugates are delivered into the target cell via receptor-mediated transcytosis, where the siRNA is delivered to the cell cytoplasm after it exits the endosome. To treat diseases and conditions, such as cancers and autoimmune diseases, the siRNA can be efficiently passed through the BBB to modulate an immune response. The small size of nanobodies allows more efficient targeted delivery than typical antibody systems, while conjugation strategies involving click chemistry permit the multiplexed loading of siRNA to nanobodies for increased therapeutic effects.
Absstract of: WO2026089702A1
The invention relates to a hybrid nanocarrier system comprising engineered metal nanoparticles (MeNP), a flavonoid (Fl), a Raman-active molecule (RAM), poly(allylamine hydrochloride) (PAH), genetic material (GM), and poly(styrene sulfonate) (PSS), designed for use in fields such as gene therapy, cancer treatment, chemotherapy, treatment of genetic diseases, innovative vaccine technologies, the production of innovative antibiotics for antibacterial and antimicrobial therapies, drug delivery, the dietary supplement market, Raman imaging systems, biotechnological applications, and the agrochemical industry.
Absstract of: US20260115136A1
Embodiments relate to acellular nanocomposite hydrogels exhibiting extracellular matrix (ECM)-like mechanics and self-healing properties. In particular, embodiments relate to nanocomposite hydrogels including network-forming biopolymers and anisotropic hairy nanoparticle linkers configured to convert the biopolymers to ECM-like analogues via ionic and dynamic covalent bonds. Embodiments further relate to method of forming the nanocomposite hydrogels and to methods of regenerating tissue including integrating the nanocomposite hydrogels with host tissues.
Absstract of: WO2026090174A1
The present disclosure provides compositions and methods for delivering therapeutic agents to particular tissues or cells in a subject. The composition disclosed herein combines unique properties of porous micro- or nano-particles with host-guest chemistry provided by functionalized silicon particle, offering a versatile approach to addressing the challenges associated with delivering therapeutic agents to target tissues or sites within the body. The present disclosure also provides a method for synthesizing a composition capable of delivering therapeutic agents to particular tissues or cells in a subject.
Absstract of: AU2023366354A1
Provided herein are novel compositions and methods for treating melanocytic disease. Provided herein are novel compositions and methods of treating diseases arising from gain-of-function NRAS and BRAF variants including cancer, in particular melanoma, as well as congenital melanocytic naevi (CMN) and acquired melanocytic naevi (AMN).
Absstract of: US20260115313A1
An antibody-conjugated liposome, particularly a nanoparticle. The surface of the nanoparticle contains antibodies. The number of the antibodies is 5-60, preferably 5-50, and more preferably 5-40. The nanoparticle, for example, a liposome, can more effectively exert a therapeutic effect on tumor and improve multidrug resistance of tumor, thereby overcoming the technical prejudice that it is commonly considered that the more antibodies on a surface of a liposome, the better the target cell binding effect, and laying a foundation for further clinical development.An antibody-conjugated liposome, particularly a nanoparticle, the surface of which contains antibodies, and the number of the antibodies is 5-60, preferably 5-50, and more preferably 5-40. The nanoparticle, such as a liposome, can more effectively exert a therapeutic effect on tumors and reduce the multidrug resistance of tumors. This overcomes the generally accepted technical bias that more antibodies on the surface of a liposome lead to better binding with target cells, thereby laying the foundation for further clinical development.
Absstract of: WO2026090513A1
The present disclosure relates to methods and nanoparticles for targeting a fibroblast activation protein (FAP)-expressing disorder.
Absstract of: WO2026085715A1
The present invention belongs to the field of biomedicine. Provided are an influenza nanoparticle vaccine, and a preparation method therefor and the use thereof. A fusion protein containing an influenza virus strain HA protein or a fragment thereof, an antigenic epitope of the influenza virus protein, and ferritin, as an antigen, can induce an immune response effect against an influenza virus, and a vaccine composed of the fusion protein and an MF59 adjuvant can induce a protection effect against viral challenge and have a good cross-protection effect.
Absstract of: WO2026090590A1
The present invention generally relates at least in part to gene delivery vehicles, and more specifically, in some embodiments, DNA delivery vehicles for the treatment of human or veterinary conditions.
Absstract of: WO2026090556A1
A biological nanoparticle for targeted therapeutic delivery is provided. The biological nanoparticle includes a plurality of extracellular vesicles. Characteristically, each extracellular vesicle contains a microRNA, which has been modified with ExoMotif sequences to enhance selective loading into the vesicles during their biogenesis. The microRNA is configured to inhibit plaque formation and vascular calcification. Additionally, a hydroxyapatite-binding peptide (HABP) is conjugated to the surface of each extracellular vesicle, facilitating targeted delivery to calcified tissues. This configuration enables the nanoparticle to specifically target areas of vascular calcification, where it can deliver the microRNA to modulate cellular behavior.
Absstract of: WO2026090311A1
Described herein are compositions comprising "amphiphilic click reactive anchors" (ACRAs) that efficiently incorporate into natural and synthetic membranous structures on cells, vesicles, liposomes, lipid nanoparticles, and other materials, and methods of use thereof, e.g., for biological and chemical analysis, drug delivery, and imaging.
Absstract of: WO2026089032A1
The main purpose of the present invention is to develop a DDS useful for treating metastatic cancer. A polyion complex according to an embodiment of the present invention comprises: a block copolymer having a hydrophilic polymer segment and a poly(amino acid) segment; and a nucleic acid, wherein the poly(amino acid) segment includes two or more cationic amino acid residues and two or more hydrophobic amino acid residues, the hydrophobic amino acid residues are arranged alternately and/or randomly, and the hydrophobic amino acid residues include hydrophobic amino acid residues having a side chain CLogP value of 3 or more. The polyion complex has an average particle diameter of 100 nm or more.
Absstract of: AU2024357528A1
Disclosed herein are methods for delaying the onset of type I diabetes and preventing nosocomial infections by administering PEG-b-PPS nanocarriers loaded with rapamycin. This invention aims to reduce the frequency of visits to a transfusion clinic, reduce the costs of treatments, and reduce adverse side effects, without reducing the effects of the islet transplant. This is accomplished by the use of a nanocarrier which targets treatment to the desired location.
Absstract of: US20260115138A1
The present disclosure relates to lipid nanoparticles and methods of delivering active agents to target organs, tissues, or cells by utilizing the lipid nanoparticles.
Absstract of: AU2024341463A1
The disclosure provides ionizable lipids for constructing lipid nanoparticles. The disclosure further provides conjugates comprising a targeting moiety and a lipid nanoparticle (LNP) encapsulating a therapeutic agent (e.g., payload) for delivery to immune cells, hematopoietic stem cells (HSCs), or liver cells. The conjugates can be delivered to cells ex vivo or formulated in a pharmaceutical composition to be directly administered to a subject in need thereof (e.g., via in vivo administration).
Nº publicación: AU2024340178A1 30/04/2026
Applicant:
THE UNIV OF MELBOURNE
THE UNIVERSITY OF MELBOURNE
Absstract of: AU2024340178A1
Bioactive nanoparticle compositions containing metal ions, phenolic ligands, bioactive agents, and seeding agents are provided, as are methods for their preparation. Through variation of one or more of the components of the compositions, the bioactive nanoparticles can be formulated to target specific sites in vivo, for example specific organs.
BOPI
Electronic site
